October 11, 2025CephalalgiaOpen Access

Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase 3 trial shows rimegepant reduces monthly migraine days in Chinese adults, suggesting safety and tolerability.

Rimegepant reduced monthly migraine days by an average of −4.4 during long-term treatment.
A total of 240 participants were treated, with 86.3% completing the study successfully.
Most participants reported at least one treatment-emergent adverse event, but none were serious or led to discontinuation.
The study demonstrates that rimegepant has a favorable long-term safety profile in Chinese adults.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark